JP2023524039A5 - - Google Patents

Info

Publication number
JP2023524039A5
JP2023524039A5 JP2022566066A JP2022566066A JP2023524039A5 JP 2023524039 A5 JP2023524039 A5 JP 2023524039A5 JP 2022566066 A JP2022566066 A JP 2022566066A JP 2022566066 A JP2022566066 A JP 2022566066A JP 2023524039 A5 JP2023524039 A5 JP 2023524039A5
Authority
JP
Japan
Prior art keywords
approximately
dose
compound
subject
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022566066A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023524039A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/029539 external-priority patent/WO2021222342A1/en
Publication of JP2023524039A publication Critical patent/JP2023524039A/ja
Publication of JP2023524039A5 publication Critical patent/JP2023524039A5/ja
Priority to JP2026087958A priority Critical patent/JP2026127654A/ja
Pending legal-status Critical Current

Links

JP2022566066A 2020-04-29 2021-04-28 T型カルシウムチャネルモジュレーターを使用する方法 Pending JP2023524039A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026087958A JP2026127654A (ja) 2020-04-29 2026-05-26 T型カルシウムチャネルモジュレーターを使用する方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063017140P 2020-04-29 2020-04-29
US63/017,140 2020-04-29
US202063050410P 2020-07-10 2020-07-10
US63/050,410 2020-07-10
US202063082946P 2020-09-24 2020-09-24
US63/082,946 2020-09-24
PCT/US2021/029539 WO2021222342A1 (en) 2020-04-29 2021-04-28 Methods of use of t-type calcium channel modulators

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026087958A Division JP2026127654A (ja) 2020-04-29 2026-05-26 T型カルシウムチャネルモジュレーターを使用する方法

Publications (2)

Publication Number Publication Date
JP2023524039A JP2023524039A (ja) 2023-06-08
JP2023524039A5 true JP2023524039A5 (cg-RX-API-DMAC7.html) 2024-05-09

Family

ID=78373913

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022566066A Pending JP2023524039A (ja) 2020-04-29 2021-04-28 T型カルシウムチャネルモジュレーターを使用する方法
JP2026087958A Pending JP2026127654A (ja) 2020-04-29 2026-05-26 T型カルシウムチャネルモジュレーターを使用する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026087958A Pending JP2026127654A (ja) 2020-04-29 2026-05-26 T型カルシウムチャネルモジュレーターを使用する方法

Country Status (11)

Country Link
US (1) US12697331B2 (cg-RX-API-DMAC7.html)
EP (1) EP4142764A4 (cg-RX-API-DMAC7.html)
JP (2) JP2023524039A (cg-RX-API-DMAC7.html)
KR (1) KR20230018384A (cg-RX-API-DMAC7.html)
CN (1) CN115776894A (cg-RX-API-DMAC7.html)
AU (1) AU2021263804A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022021946A2 (cg-RX-API-DMAC7.html)
CA (1) CA3177277A1 (cg-RX-API-DMAC7.html)
IL (1) IL297642A (cg-RX-API-DMAC7.html)
MX (1) MX2022013595A (cg-RX-API-DMAC7.html)
WO (1) WO2021222342A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021007487A1 (en) 2019-07-11 2021-01-14 Praxis Precision Medicines, Inc. Formulations of t-type calcium channel modulators and methods of use thereof
CA3243616A1 (en) * 2022-02-03 2023-08-10 Praxis Precision Medicines, Inc. TREATMENT METHODS USING T-TYPE CALCIUM CHANNEL MODULATORS
WO2023192885A2 (en) * 2022-03-28 2023-10-05 Praxis Precision Medicines, Inc. Methods of using oligomeric compounds to treat scn2a-related disorders
US20250295646A1 (en) * 2022-05-09 2025-09-25 Praxis Precision Medicines, Inc. Methods of use of t-type calcium channel modulators
CN121127457A (zh) * 2023-03-02 2025-12-12 普拉西斯精密医药公司 T型钙通道调节剂的结晶盐和其使用方法
AU2024230578A1 (en) * 2023-03-02 2025-09-04 Praxis Precision Medicines, Inc. Crystalline salt forms of n-((1-(2-(tert-butylamino)-2-oxoethyl)piperidin-4-yl)methyl)-3-chloro-5-fluorobenzamide and methods of use thereof
WO2025059511A1 (en) 2023-09-15 2025-03-20 Praxis Precision Medicines, Inc. Elsunersen / prax-222 for use in the treatment of scn2a-related disorders
WO2025188619A1 (en) * 2024-03-04 2025-09-12 Praxis Precision Medicines, Inc. Methods of treating parkinson's disease with t-type calcium channel modulators

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8377968B2 (en) * 2008-06-02 2013-02-19 Zalicus Pharmaceuticals, Ltd. N-piperidinyl acetamide derivatives as calcium channel blockers
EP3364993B1 (en) * 2015-10-22 2022-11-09 Cavion, Inc. Methods for treating angelman syndrome
RU2746188C2 (ru) * 2015-11-12 2021-04-08 Афаски, Инк. Ингибиторы ионного канала, фармацевтические составы и применение
HRP20220463T1 (hr) * 2016-12-16 2022-05-27 Idorsia Pharmaceuticals Ltd Farmaceutska kombinacija koja sadrži blokator kalcijevih kanala t-tipa
WO2018118101A1 (en) * 2016-12-21 2018-06-28 Praxis Precision Medicines, Inc. T-type calcium channel modulators and methods of use thereof
SG11202004329TA (en) * 2017-11-10 2020-06-29 Marinus Pharmaceuticals Inc Ganaxolone for use in treating genetic epileptic disoders
JP7480131B2 (ja) * 2018-10-03 2024-05-09 カビオン・インコーポレイテッド (r)-2-(4-イソプロピルフェニル)-n-(1-(5-(2,2,2-トリフルオロエトキシ)ピリジン-2-イル)エチル)アセトアミドを使用した本態性振戦の処置
WO2021007487A1 (en) * 2019-07-11 2021-01-14 Praxis Precision Medicines, Inc. Formulations of t-type calcium channel modulators and methods of use thereof
US20250295646A1 (en) * 2022-05-09 2025-09-25 Praxis Precision Medicines, Inc. Methods of use of t-type calcium channel modulators

Similar Documents

Publication Publication Date Title
TWI335217B (en) Pharmaceutical formulations of modafinil
JP7650929B2 (ja) 成人における焦点てんかんの処置のための合成経皮的カンナビジオール
JP2024075655A5 (ja) 鏡像異性体的に純粋なブプロピオンの医薬の製造における使用
CN101600438A (zh) 疼痛疾病治疗剂
JP2026035701A5 (cg-RX-API-DMAC7.html)
EP3678643B1 (en) Sublingual epinephrine tablets
JP2018507243A5 (cg-RX-API-DMAC7.html)
JP2023535744A5 (cg-RX-API-DMAC7.html)
US20220096475A1 (en) Method for treating sarcoidosis-associated pulmonary hypertension
JP2021152060A (ja) アカンプロセートおよびd−サイクロセリンを使用する組み合わせ療法
JP2022521233A5 (cg-RX-API-DMAC7.html)
US20230233496A1 (en) Levodopa fractionated dose composition and use
US11304923B2 (en) Use of a benzoate containing composition to treat glycine encephalopathy
US5985933A (en) Methods for treating central and peripheral nerve pain
CN109172550B (zh) 一种复合麻醉药物
Grøn Bromocriptine versus placebo in levodopa treated patients with Parkinson's disease
US8785469B2 (en) Method of treating atherogenic dyslipidemia
JP2022506019A (ja) 高用量の放出調節フペルジン製剤の使用
JP2024059812A5 (ja) 鏡像異性体的に濃縮された、または純粋なブプロピオンの組成物
JP2021530568A5 (cg-RX-API-DMAC7.html)
JP2021509671A5 (cg-RX-API-DMAC7.html)
JP2024502466A5 (cg-RX-API-DMAC7.html)
US12161612B2 (en) Methods and compositions for reducing symptoms of Parkinson's disease
JP2025505578A5 (cg-RX-API-DMAC7.html)
JP2023533472A5 (cg-RX-API-DMAC7.html)